Literature DB >> 9107428

Ras oncogene mutations in childhood brain tumors.

T H Maltzman1, B A Mueller, J Schroeder, J C Rutledge, K Patterson, S Preston-Martin, E M Faustman.   

Abstract

Although N-nitroso compounds (NNC) are ubiquitous in the human environment and are known neurocarcinogens in animal models, results of epidemiological studies have not yet convincingly associated NNCs with brain tumor occurrence in humans. Animal studies have suggested that specific codons (12, 13, and 61) in the ras family are mutable by exposure to NNCs. The purpose of this study was to measure the presence of mutations in the ras family of oncogenes in tissue from childhood brain (CB) tumors as a preliminary step toward investigating their potential use as biomarkers of chemical exposure. DNA was extracted from paraffin-embedded formalin-fixed CB tumors from tissues resected during neurosurgical operations. Using the PCR, designed RFLP-screening methods, and sequencing, we attempted to screen brain tumors from 46 children for the presence of H, K, and N-ras mutations at codons 12, 13, and 61. Screening for oncogene mutations using PCR, RFLP methods, and DNA sequencing was successfully completed for a high proportion of the available specimens. Astrocytoma specimens from three children for whom screening with PCR was successfully completed were found to contain CAA-->GAA point mutations in K-ras at codon 61. None of the specimens contained mutations at any of the other locations. These results, although preliminary, provide a potential clue for future mechanistic studies of CB tumors. The possible roles of NNCs in inducing this mutation, or of this mutation as an early or late event in tumor progression, however, remain unclear.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9107428

Source DB:  PubMed          Journal:  Cancer Epidemiol Biomarkers Prev        ISSN: 1055-9965            Impact factor:   4.254


  7 in total

Review 1.  Will kinase inhibitors make it as glioblastoma drugs?

Authors:  Ingo K Mellinghoff; Nikolaus Schultz; Paul S Mischel; Timothy F Cloughesy
Journal:  Curr Top Microbiol Immunol       Date:  2012       Impact factor: 4.291

2.  Trametinib for progressive pediatric low-grade gliomas.

Authors:  Maria Kondyli; Valérie Larouche; Christine Saint-Martin; Benjamin Ellezam; Lauranne Pouliot; Daniel Sinnett; Geneviève Legault; Louis Crevier; Alex Weil; Jean-Pierre Farmer; Nada Jabado; Sébastien Perreault
Journal:  J Neurooncol       Date:  2018-08-10       Impact factor: 4.130

3.  Infrequent RAS mutation is not associated with specific histological phenotype in gliomas.

Authors:  Yasuhide Makino; Yoshiki Arakawa; Ema Yoshioka; Tomoko Shofuda; Sachiko Minamiguchi; Takeshi Kawauchi; Masahiro Tanji; Daisuke Kanematsu; Masahiro Nonaka; Yoshiko Okita; Yoshinori Kodama; Masayuki Mano; Takanori Hirose; Yohei Mineharu; Susumu Miyamoto; Yonehiro Kanemura
Journal:  BMC Cancer       Date:  2021-09-15       Impact factor: 4.638

Review 4.  Behavioral genetics of the depression/cancer correlation: a look at the Ras oncogene family and the 'cerebral diabetes paradigm'.

Authors:  Janet K Brewer
Journal:  J Mol Neurosci       Date:  2008-06-18       Impact factor: 3.444

5.  Oncogenic RAF1 rearrangement and a novel BRAF mutation as alternatives to KIAA1549:BRAF fusion in activating the MAPK pathway in pilocytic astrocytoma.

Authors:  D T W Jones; S Kocialkowski; L Liu; D M Pearson; K Ichimura; V P Collins
Journal:  Oncogene       Date:  2009-04-13       Impact factor: 9.867

Review 6.  MAPK pathway activation in pilocytic astrocytoma.

Authors:  David T W Jones; Jan Gronych; Peter Lichter; Olaf Witt; Stefan M Pfister
Journal:  Cell Mol Life Sci       Date:  2011-12-13       Impact factor: 9.261

7.  Tandem duplication producing a novel oncogenic BRAF fusion gene defines the majority of pilocytic astrocytomas.

Authors:  David T W Jones; Sylvia Kocialkowski; Lu Liu; Danita M Pearson; L Magnus Bäcklund; Koichi Ichimura; V Peter Collins
Journal:  Cancer Res       Date:  2008-11-01       Impact factor: 12.701

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.